AI Engines For more Details: Perplexity Kagi Labs You
Breast Cancer: Docetaxel is commonly used in the treatment of breast cancer, both in the adjuvant (after surgery) and metastatic (advanced) settings. It may be used alone or in combination with other chemotherapy drugs or targeted therapies. Docetaxel-based regimens have demonstrated efficacy in improving survival rates and reducing the risk of cancer recurrence in patients with breast cancer.
Non-Small Cell Lung Cancer (NSCLC): Docetaxel is indicated for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based chemotherapy. It may be used as a single agent or in combination with other chemotherapy drugs.
Prostate Cancer: Docetaxel is approved for the treatment of metastatic hormone-refractory prostate cancer (mHRPC), also known as castration-resistant prostate cancer (CRPC). It is often used in combination with prednisone or other corticosteroids to improve outcomes in patients with advanced prostate cancer.
Gastric Cancer: Docetaxel is sometimes used in the treatment of advanced or metastatic gastric (stomach) cancer, particularly in combination with other chemotherapy drugs such as cisplatin and fluorouracil (5-FU). This combination therapy may be used as a first-line or second-line treatment option.
Head and Neck Cancer: Docetaxel is utilized in the treatment of locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN), often in combination with other chemotherapy agents or as part of concurrent chemoradiotherapy regimens.
Other Cancers: Docetaxel may also be used in the treatment of other cancers, including ovarian cancer, bladder cancer, and soft tissue sarcomas, either as a single agent or in combination with other chemotherapy drugs.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 0 | 1 | Bifidobacterium angulatum | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.1 | -0.1 | |
| ADHD | 0.4 | 0.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | 0 |
| Allergic Rhinitis (Hay Fever) | 1.1 | 0.3 | 2.67 |
| Allergies | 1.3 | 1.3 | 0 |
| Allergy to milk products | 0.9 | 0.7 | 0.29 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 1.7 | 1.8 | -0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.7 | |
| Ankylosing spondylitis | 0.8 | 0.5 | 0.6 |
| Anorexia Nervosa | 0.7 | 1.6 | -1.29 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 1.7 | 0.8 | 1.13 |
| Atherosclerosis | 1.2 | 0.6 | 1 |
| Atrial fibrillation | 1.3 | 0.7 | 0.86 |
| Autism | 2.4 | 2.2 | 0.09 |
| Autoimmune Disease | 0.1 | 0.6 | -5 |
| benign prostatic hyperplasia | 0.5 | -0.5 | |
| Bipolar Disorder | 1 | 0.1 | 9 |
| Brain Trauma | 0.1 | 0.6 | -5 |
| Cancer (General) | 0.8 | -0.8 | |
| Carcinoma | 0.7 | 0.7 | 0 |
| Celiac Disease | 1.3 | 0.7 | 0.86 |
| Cerebral Palsy | 1 | 0.5 | 1 |
| Chronic Fatigue Syndrome | 1 | 0.7 | 0.43 |
| Chronic Kidney Disease | 0.6 | 0.1 | 5 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | -0.1 | |
| Chronic Urticaria (Hives) | 0.5 | 0.7 | -0.4 |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | 0 |
| Cognitive Function | 0.7 | 0.6 | 0.17 |
| Colorectal Cancer | 1.8 | 1.1 | 0.64 |
| Constipation | 0.5 | 0.1 | 4 |
| Coronary artery disease | 1.1 | -1.1 | |
| COVID-19 | 1.3 | 1 | 0.3 |
| Crohn's Disease | 2 | 1.3 | 0.54 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.6 | 0.5 | 0.2 |
| Depression | 2.2 | 1.3 | 0.69 |
| Dermatomyositis | 0.1 | -0.1 | |
| Eczema | 0.5 | 1.4 | -1.8 |
| Endometriosis | 0.7 | 0.1 | 6 |
| Epilepsy | 1.8 | 0.7 | 1.57 |
| erectile dysfunction | 0.9 | 0.1 | 8 |
| Fibromyalgia | 0.7 | 1.1 | -0.57 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 1.8 | 0 |
| gallstone disease (gsd) | 1.2 | 0.2 | 5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.6 | |
| Generalized anxiety disorder | 0.5 | 1 | -1 |
| giant cell arteritis | 0.5 | -0.5 | |
| Gout | 0.5 | 0.5 | 0 |
| Graves' disease | 0.7 | 0.6 | 0.17 |
| Gulf War Syndrome | 0.5 | 0.7 | -0.4 |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 1.2 | 0.6 | 1 |
| Heart Failure | 1 | 0.2 | 4 |
| hemorrhagic stroke | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| High Histamine/low DAO | 1.1 | 0.1 | 10 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.7 | -0.7 | |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 0.7 | 1.4 | -1 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 1.7 | 1.7 | |
| IgA nephropathy (IgAN) | 0.6 | 0.7 | -0.17 |
| Inflammatory Bowel Disease | 2.3 | 2.2 | 0.05 |
| Insomnia | 0.5 | 0.5 | 0 |
| Intelligence | 0.9 | 0.1 | 8 |
| Intracranial aneurysms | 0.6 | 0.6 | |
| Irritable Bowel Syndrome | 1.7 | 1.2 | 0.42 |
| ischemic stroke | 0.7 | 0.5 | 0.4 |
| Liver Cirrhosis | 1.8 | 1.1 | 0.64 |
| Long COVID | 0.7 | 0.9 | -0.29 |
| Low bone mineral density | 0.1 | -0.1 | |
| Mast Cell Issues / mastitis | 0.1 | -0.1 | |
| ME/CFS with IBS | 0.5 | 0.6 | -0.2 |
| ME/CFS without IBS | 0.5 | 0.7 | -0.4 |
| Menopause | 0.2 | 0.1 | 1 |
| Metabolic Syndrome | 1.8 | 2 | -0.11 |
| Mood Disorders | 2.8 | 1.2 | 1.33 |
| Multiple Sclerosis | 1.3 | 2.6 | -1 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.1 | -0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 0.8 | 0.38 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | 0 |
| Obesity | 1.2 | 2 | -0.67 |
| obsessive-compulsive disorder | 1.2 | 0.6 | 1 |
| Osteoarthritis | 0.9 | 0.6 | 0.5 |
| Osteoporosis | 1 | 0.5 | 1 |
| Parkinson's Disease | 1.8 | 1.9 | -0.06 |
| Polycystic ovary syndrome | 2 | 1.1 | 0.82 |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.1 | 4 |
| Premenstrual dysphoric disorder | 0.1 | 0.1 | 0 |
| primary biliary cholangitis | 0.5 | -0.5 | |
| Primary sclerosing cholangitis | 1 | 0.7 | 0.43 |
| Psoriasis | 1.2 | 0.9 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 1.7 | -1.13 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 1.9 | 1.2 | 0.58 |
| Sjögren syndrome | 0.2 | 0.9 | -3.5 |
| Sleep Apnea | 0.1 | 0.5 | -4 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.1 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 1.2 | 0.7 | 0.71 |
| Systemic Lupus Erythematosus | 1.6 | 0.2 | 7 |
| Tic Disorder | 0.2 | -0.2 | |
| Tourette syndrome | 0.5 | -0.5 | |
| Type 1 Diabetes | 1.5 | 1.3 | 0.15 |
| Type 2 Diabetes | 1.3 | 2 | -0.54 |
| Ulcerative colitis | 2.3 | 1.8 | 0.28 |
| Unhealthy Ageing | 1.1 | 0.2 | 4.5 |
| Vitiligo | 1.3 | 0.7 | 0.86 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
